Printer Friendly

CYTOGEN AND KNOLL A.G. CO-MARKETING AGREEMENT FINALIZED

 CYTOGEN AND KNOLL A.G. CO-MARKETING AGREEMENT FINALIZED
 PRINCETON, N.J., Dec. 18 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) announced today it has finalized its agreement with Knoll Pharmaceuticals ("Knoll"), the U.S. based pharmaceutical operation owned by B.A.S.F. A.G. and its subsidiary Knoll A.G., a major worldwide pharmaceutical company, for the U.S. co-promotion of its first cancer diagnostic imaging agents, OncoScint CR103 for colorectal cancer and OncoScint OV103 for ovarian cancer.
 The comprehensive agreement includes the joint promotion and sales of Cytogen Corporation's first two OncoScint products, a supply agreement in which Cytogen will provide Knoll with finished goods for distribution, and a product development program covering Cytogen's follow-on colorectal cancer imaging agent, OncoScint CR372, also to be jointly marketed by the companies. In addition to sharing revenue and certain marketing expenses for the products, Cytogen will receive an undisclosed up-front payment, milestone payments upon the FDA approval of OncoScint colorectal and OncoScint ovarian products, and monetary clinical development support.
 Cytogen is already establishing a specialty sales force which, together with the Knoll sales representatives, will reach surgeons, oncologists, and nuclear medicine physicians. Knoll Pharmaceuticals is located in Whippany, N.J.
 In commenting on this agreement, George W. Ebright, Cytogen's chairman of the goard and CEO, said, "The Cytogen/Knoll collaboration will allow the successful commercialization of our first two products, with minimal risk to our shareholders, while enabling Cytogen to establish its own selling capability which is an important strategic objective. Cytogen intends to capture and hold the leading market share for cancer imaging and this is an important step in that direction."
 Cytogen Corporation is a biopharmaceutical company which has developed proprietary systems for linking drugs and diagnostic agents to monoclonal antibodies in order to optimize the function of the antibody as a delivery vehicle. The company currently has six cancer imaging agents under development and two of these imaging agents, for colorectal and ovarian cancer, are awaiting FDA marketing approval. Also under development are two cancer therapy agents.
 /delval/
 -0- 12/18/91
 /CONTACT: Laura M. Hahn of Cytogen, 609-987-8221/
 (CYTO) CO: Cytogen Corporation; Knoll A.G. ST: New Jersey IN: MTC SU:


LJ -- PH005 -- 3324 12/18/91 10:25 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 18, 1991
Words:371
Previous Article:STONE & WEBSTER ANNOUNCES DIVIDEND
Next Article:APPLIED IMMUNE SCIENCES AND CAREMARK FORM JOINT VENTURE TO ESTABLISH CELL THERAPY CENTERS FOR TREATMENT OF AIDS
Topics:


Related Articles
CYTOGEN CORPORATION ANNOUNCES FOURTH QUARTER RESULTS
FDA APPROVES CYTOGEN PRODUCT AS FIRST MAB-BASED CANCER IMAGING AGENT IN THE UNITED STATES
FDA APPROVES ONCOSCINT AND INDICLOR FOR COLORECTAL AND OVARIAN CANCER DETECTION; FIRST CANCER IMAGING AGENT BASED ON A MONOCLONAL ANTIBODY
CYTOGEN UPDATES STOCKHOLDERS ON MARKETING OF ONCOSCINT(R) CR/OV, PRODUCT DEVELOPMENT ACTIVITIES & CYTORAD DEVELOPMENTS
CYTOGEN CORPORATION REPORTS ON DEVELOPMENTS CONNECTED WITH SEC FILING
CYTOGEN REPORTS YEAR END RESULTS AND CITES DECREASE IN 1994 OPERATING EXPENSES
CYTOGEN SIGNS TWO PARTNERS TO MARKET ONCOSCINT(R) CR/OV OUTSIDE U.S.
FDA Licenses Cytogen's Prostate Cancer Imaging Product
Cardiovascular Diagnostics, Inc. Enters Into Second Development and Co-Marketing Agreement With Knoll AG
Cardiovascular Diagnostics to Receive Second Milestone Payment from Knoll for Ancrod Stroke Treatment Test Development

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters